The estimated Net Worth of Martina M.D. Flammer is at least $20.7 Миллион dollars as of 6 September 2024. Dr Flammer owns over 149,002 units of Insmed Inc stock worth over $18,563,695 and over the last 5 years he sold INSM stock worth over $1,181,746. In addition, he makes $934,413 as Chief Medical Officer at Insmed Inc.
Sign up
Dr D INSM stock SEC Form 4 insiders trading
Dr has made over 16 trades of the Insmed Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 149,002 units of INSM stock worth $3,392,776 on 6 September 2024.
The largest trade he's ever made was exercising 149,002 units of Insmed Inc stock on 6 September 2024 worth over $3,392,776. On average, Dr trades about 15,553 units every 41 days since 2020. As of 6 September 2024 he still owns at least 255,136 units of Insmed Inc stock.
You can see the complete history of Dr Flammer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Martina Flammer M.B.A., M.D. biography
Dr. Martina Flammer M.B.A., M.D. is the Chief Medical Officer at Insmed Inc.
What is the salary of Dr D?
As the Chief Medical Officer of Insmed Inc, the total compensation of Dr D at Insmed Inc is $934,413. There are 5 executives at Insmed Inc getting paid more, with William Lewis having the highest compensation of $7,175,090.
How old is Dr D?
Dr D is 57, he's been the Chief Medical Officer of Insmed Inc since . There are 8 older and 15 younger executives at Insmed Inc. The oldest executive at Insmed Inc is Steinar Engelsen, 70, who is the Independent Director.
What's Dr D's mailing address?
Martina's mailing address filed with the SEC is 700 US HIGHWAY 202/206, , BRIDGEWATER, NJ, 08807.
Insiders trading at Insmed Inc
Over the last 22 years, insiders at Insmed Inc have traded over $46,121,705 worth of Insmed Inc stock and bought 1,080,212 units worth $8,226,993 . The most active insiders traders include Llc Fmr, William Lewis и Dennis M Lanfear. On average, Insmed Inc executives and independent directors trade stock every 38 days with the average trade being worth of $2,452,158. The most recent stock trade was executed by Orlov S Nicole Schaeffer on 10 September 2024, trading 37,575 units of INSM stock currently worth $407,689.
What does Insmed Inc do?
insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. the company is dedicated to developing and bringing to market therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. headquartered in bridgewater, nj, we are a rapidly growing company with offices in seven countries.
What does Insmed Inc's logo look like?
Complete history of Dr Flammer stock trades at Insmed Inc
Insmed Inc executives and stock owners
Insmed Inc executives and other stock owners filed with the SEC include:
-
William Lewis,
Chairman of the Board, President, Chief Executive Officer -
Roger Adsett,
Chief Operating Officer -
Christine Pellizzari,
Chief Legal Officer -
S. Nicole Schaeffer,
Chief People Strategy Officer -
William H. Lewis J.D., M.B.A.,
Pres, CEO & Chairman -
Dr. Martina Flammer M.B.A., M.D.,
Chief Medical Officer -
John Goll,
Chief Accounting Officer -
Roger Adsett,
Chief Operating Officer -
Christine A. Pellizzari J.D.,
Consultant -
Sara M. Bonstein MBA,
Chief Financial Officer -
John Goll III,
Sr. VP & Chief Accounting Officer -
David Brennan,
Lead Independent Director -
Alfred Altomari,
Independent Director -
Steinar Engelsen,
Independent Director -
David McGirr,
Independent Director -
Melvin Sharoky,
Independent Director -
Leo Lee,
Independent Director -
Elizabeth Anderson,
Independent Director -
Clarissa Desjardins,
Independent Director -
Carol Schafer,
Director -
Martina Flammer,
Chief Medical Officer -
John Soriano,
Chief Compliance Officer -
Sara Bonstein,
Chief Financial Officer -
S. Nicole Schaeffer,
Chief People Strategy Officer -
Mandy Fahey,
Sr. Director of Corp. Communications -
Michael Alexander Smith,
Sr. VP & Gen. Counsel -
John D. Soriano J.D.,
Chief Compliance Officer -
Eleanor Barisser,
Associate Director of Investor Relations -
Paolo Tombesi,
Chief Financial Officer -
Paul Streck,
Chief Medical Officer -
Eugene Jeffrey Sullivan,
Chief Medical Officer -
Myrtle S Potter,
Director -
Donald J Jr Hayden,
Director -
Geoffrey Allan,
President, CEO and Chairman -
Stephen C. Glover,
President Follow-on Biologics -
Doug Farrar,
Vice President, ITP -
Michael Duncan,
Principal Financial Officer -
Thomas A Keuer,
VP, ITP (Subsidiary) -
Philip J Young,
Chief Business Officer and EVP -
Ronald D Gunn,
Executive Vice President -
Mark Quigley,
Vice President, Quality -
Randall W Whitcomb,
Director -
Peggy Berry,
Vice President, Regulatory -
Renu Gupta,
Chief Medical Officer -
Richard S Kollender,
Director -
Matthew Pauls,
Chief Commercial Officer -
Llc Fmr,
10% owner -
Andrea Holtzman Drucker,
Senior V.P., General Counsel -
Nicholas A. Jr. La Bella,
Chief Scientific Officer -
Kenneth G Condon,
Director -
Kevin P Tully,
Executive VP & CFO -
Timothy Whitten,
President & CEO -
Graham K Crooke,
Director -
Nicholas Lee Gurreri,
Senior VP, Commercial Ops -
Dennis M Lanfear,
Director -
John Drayton Wise,
Chief Commercial Officer -
Michael Alexander Smith,
Chief Legal Officer